Ovarian function with a novel combined contraceptive vaginal ring

By Mulders Titia M.T.  

Human Reproduction, Vol. 17, Iss. 10, 2002-10 ,pp. : 2594-2599

Oxford University Press

Access to resources Recommend Favorite

Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone

By Milsom I.   Lete I.   Bjertnaes A.   Rokstad K.   Lindh I.   Gruber C.J.   Birkhäuser M.H.   Aubeny E.   Knudsen T.   Bastianelli C.  

Human Reproduction, Vol. 21, Iss. 9, 2006-09 ,pp. : 2304-2311

Oxford University Press

Access to resources Recommend Favorite

Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms.

By Acién P   Mauri M   Gutierrez M  

Human Reproduction, Vol. 12, Iss. 3, 1997-03 ,pp. : 423-429

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation

By Zegers-Hochschild F.  

Human Reproduction, Vol. 15, Iss. 10, 2000-10 ,pp. : 2093-2097

Oxford University Press

Access to resources Recommend Favorite

Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 g ethinylestradiol and 150 g levonorgestrel: a randomized trial

By Oddsson K.  

Human Reproduction, Vol. 20, Iss. 2, 2005-02 ,pp. : 557-562

Oxford University Press

Access to resources Recommend Favorite